心脏植入物开发商Encore Medical(EMI.US)IPO定价5美元/股 拟筹资1500万美元

Group 1 - Encore Medical plans to issue 3 million shares at a price of $5 per share, aiming to raise $15 million through its IPO [1] - The company is headquartered in Eagan, Minnesota, and specializes in developing and manufacturing interatrial septal occluders for repairing heart defects such as patent foramen ovale (PFO) [1] - Encore Medical's device has been approved for sale in the European Union, but it has not yet received regulatory approval for sale in the United States; however, it has FDA approval to conduct trials for market clearance [1] Group 2 - The company's projected revenue for the 12 months ending September 30, 2025, is $2 million [1]